Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .
All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV . Inclusion Criteria: * Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV. * All patients will be received steroids , MMF and Angiotensin Converting Enzyme. Exclusion Criteria: * Patients diagnosed with lupus nephritis class I,II,V and VI. * Patients received Cyclophosphamide in stead of MMF.
Study Type
OBSERVATIONAL
Enrollment
60
group1 received chloroquine .
Group 2 received hydroxychloroquine
Fatma Gheet
Tanta, Egypt
RECRUITINGFundus examination as screening test
Detection of chloroquine and hydroxychloroquine related retinal toxicity at early stage.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.